August 20, 2026
Capital Access Group – TheraCryf £1.1m raise progressing Ox-1 to clinical trial
Capital Access Research
Capital Access Group releases a new research note following the announcement of an equity raise focusing on completing the clinic-enabling programme for the company’s Ox-1 lead clinical asset. Read more
Filter by:
Date
Title
Download
August 20, 2026
Notice of GM and Form of Proxy
August 20, 2026
TheraCryf plc Amended Articles of Association (draft)
May 14, 2026
Turner Pope Investments – Top-line Toxicology Data
April 21, 2026
Turner Pope Investments – TheraCryf plc Research Note
April 16, 2026
Capital Access Group – Patent protection potentially extending to 2046
April 14, 2026
Turner Pope Investments – indicative proposal for Ox-1 / DAT programmes
April 14, 2026
Capital Access Group – Ox-1/DAT programmes – indicative proposal
April 13, 2026
Capital Access Group – Orexin M&A demonstrates industry appetite
March 23, 2026
Capital Access Group – Ox-1 Imminent start of final toxicology study
January 5, 2026
Capital Access – Ox-1 10kg toxicology study quantity achieved
December 18, 2025
Capital Access Group – DAT asset potential value highlighted
December 3, 2025
Turner Pope Investments, Research Note on Half-Year Results
December 3, 2025
Capital Access Group – Research Note on Half-Year Results
July 15, 2025
TheraCryf LTIP Rules 2025
July 9, 2025
Voting on AGM Resolutions
June 16, 2025
Notice of AGM 2025
June 3, 2025
Cavendish – Research Note on Full Year Results
June 3, 2025
Capital Access Group – Research Note on Full Year Results
June 3, 2025
Turner Pope Investments, Research Note on Full Year Results
May 12, 2025
Capital Access Group, Research – Pharmaron contract
May 12, 2025
Cavendish, Research – CDMO/CRO Selection
March 7, 2025
Voting on GM Resolution
February 19, 2025
Cavendish, Research